Soluble ST2 and interleukin-33 levels in coronary artery disease: Relation to disease activity and adverse outcome

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Demyanets, Svitlana ^a   Speidl, Walter S ^a   Tentzeris, Ioannis ^b   Jarai, Rudolf ^b   Katsaros, Katharina M ^a,c   Farhan, Serdar ^b   Krychtiuk, Konstantin A ^a,c   Wonnerth, Anna ^a,c   Weiss, Thomas W ^b   Huber, Kurt ^b   Wojta, Johann ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IL1RL1 PROTEIN, HUMAN; IL33 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; UPREGULATION; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SOLUBILITY; TREATMENT OUTCOME;

AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, CELL SURFACE; RISK FACTORS; SOLUBILITY; TREATMENT OUTCOME;

EID: 84899672348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095055     Document Type: Article

References (33)

1. Trajkovic V, Sweet MJ, Xu D (2004) T1/ST2-an IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 15: 87-95. (Pubitemid 38523333)
2. Kakkar R, Lee RT (2008) The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 7: 827-840.
3. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490. (Pubitemid 41587888)
4. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, et al. (1999) Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 264: 397-406. (Pubitemid 29424443)
5. Miller AM, Xu D, Asquith DL, Denby L, Li Y, et al. (2008) IL-33 reduces the development of atherosclerosis. J Exp Med 205: 339-346. (Pubitemid 351281600)
6. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, et al. (2002) Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 106: 2961-2966. (Pubitemid 35424749)
7. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, et al. (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117: 1538-1549. (Pubitemid 46871338)
8. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, et al. (2013) Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol 60: 16-26.
9. Miller AM (2011) Role of IL-33 in inflammation and disease. J Inflamm (Lond) 8: 22.
10. Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, et al. (2011) Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 31: 2080-2089.
11. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, et al. (2004) Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109: 2186-2190. (Pubitemid 38625395)
12. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, et al. (2008) Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 117: 1936-1944. (Pubitemid 351543469)
13. Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, et al. (2010) Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol 55: 243-250.
14. Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, et al. (2010) ST2 and mortality in non-ST-segment elevation acute coronary syndrome. Am Heart J 159: 788-794.
15. Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, et al. (2012) Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 58: 257-266.
16. Dhillon OS, Narayan HK, Quinn PA, Squire IB, Davies JE, et al. (2011) Interleukin 33 and ST2 in non-ST-elevation myocardial infarction: comparison with Global Registry of Acute Coronary Events Risk Scoring and NT-proBNP. Am Heart J 161: 1163-1170.
17. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, et al. (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107: 721-726. (Pubitemid 36222600)
18. Dhillon OS, Narayan HK, Khan SQ, Kelly D, Quinn PA, et al. (2013) Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers? Int J Cardiol 167: 2182-2188.
19. Demyanets S, Tentzeris I, Jarai R, Katsaros KM, Farhan S, et al. (2014) An increase of interleukin-33 serum levels after coronary stent implantation is associated with coronary in-stent restenosis. Cytokine.
20. Dupont WD, Plummer WD Jr (1990) Power and sample size calculations. A review and computer program. Control Clin Trials 11: 116-128. (Pubitemid 20136185)
21. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, et al. (2012) Prognostic utility of novel biomarkers of cardiovascular stress: the framingham heart study. Circulation 126: 1596-1604.
22. Zhang K, Zhang XC, Mi YH, Liu J (2013) Predicting value of serum soluble ST2 and interleukin-33 for risk stratification and prognosis in patients with acute myocardial infarction. Chin Med J (Engl) 126: 3628-3631.
23. Tsapaki A, Zaravinos A, Apostolakis S, Voudris K, Vogiatzi K, et al. (2010) Genetic variability of the distal promoter of the ST2 gene is associated with angiographic severity of coronary artery disease. J Thromb Thrombolysis 30: 365-371.
24. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, et al. (2012) Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 58: 1673-1681.
25. Miller AM, Purves D, McConnachie A, Asquith DL, Batty GD, et al. (2012) Soluble ST2 Associates with Diabetes but Not Established Cardiovascular Risk Factors: A New Inflammatory Pathway of Relevance to Diabetes? PLoS One 7: e47830.
26. Kakkar R, Hei H, Dobner S, Lee RT (2012) Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 287: 6941-6948.
27. Bartunek J, Delrue L, Van Durme F, Muller O, Casselman F, et al. (2008) Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 52: 2166-2174.
28. Braun OO, Lu D, Aroonsakool N, Insel PA (2010) Uridine triphosphate (UTP) induces profibrotic responses in cardiac fibroblasts by activation of P2Y2 receptors. J Mol Cell Cardiol 49: 362-369.
29. Yndestad A, Marshall AK, Hodgkinson JD, Tham el L, Sugden PH, et al. (2010) Modulation of interleukin signalling and gene expression in cardiac myocytes by endothelin-1. Int J Biochem Cell Biol 42: 263-272.
30. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, et al. (2010) Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 87: 769-777.
31. Seki K, Sanada S, Kudinova AY, Steinhauser ML, Handa V, et al. (2009) Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2: 684-691.
32. Rui T, Zhang J, Xu X, Yao Y, Kao R, et al. (2012) Reduction in IL-33 expression exaggerates ischaemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc Res 94: 370-378.
33. Abston ED, Barin JG, Cihakova D, Bucek A, Coronado MJ, et al. (2012) IL-33 Independently Induces Eosinophilic Pericarditis and Cardiac Dilation: ST2 Improves Cardiac Function. Circ Heart Fail 5: 366-375.